Tuberculosis and Respiratory Diseases

The Korean Academy of Tuberculosis and Respiratory Diseases (대한결핵및호흡기학회)
권호 표지
DOI QR코드

DOI QR Code

Respiratory Review of 2011: Asthma

호흡기내과 의사를 위한 Respiratory Review of 2011

  • Yoo, Kwang-Ha (Department of Internal Medicine, Konkuk University School of Medicine)
  • 유광하 (건국대학교 의학전문대학원 내과학교실)
  • Received : 2011.06.01
  • Accepted : 2011.06.02
  • Published : 2011.08.30
Download PDF
⟨ Previous Next ⟩

Abstract

Asthma is the most common chronic illness to affect children and is a major cause of morbidity in adults, affecting 4~17% of children and 7.3~10.1% of adults, which translates to approximately 300 million people globally. This article reviews recently published data over the past 1~2 years on asthma, and covers the 3 aspects of current advancement for the diagnosis of severe asthma, including the controversy to long-acting bronchodilator treatment for treatment of asthma, and the role of long-acting anticholinergics treatment in asthma patients.

Keywords

References

  1. World Health Organization (WHO). Bronchial asthma. World Health Organization Fact Sheet No. 307. Geneva, Switzerland: WHO; 2008.
  2. Osborne M, Deffebach M. The epidemiology and natural history of asthma: Outcomes and Treatment Regimens (TENOR) study. Ann Allergy Asthma Immunol 2004;92:3-4. https://doi.org/10.1016/S1081-1206(10)61702-4
  3. Dolan CM, Fraher KE, Bleecker ER, Borish L, Chipps B, Hayden ML, et al. Design and baseline characteristics of the epidemiology and natural history of asthma. Outcomes and Treatment Regimens (TENOR) study: a large cohort of patients with severe or difficult-to-treat asthma. Ann Allergy Asthma Immunol 2004;92:32-9. https://doi.org/10.1016/S1081-1206(10)61707-3
  4. Sullivan SD, Rasouliyan L, Russo PA, Kamath T, Chipps BE; TENOR Study Group. Extent, patterns, and burden of uncontrolled disease in severe or difficult-to-treat asthma. Allergy 2007;62:126-33.
  5. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention [Internet]. GINA; 2006 [cited 2011 Aug 10]. Available from: http://www.ginasthma.org/.
  6. Moore WC, Bleecker ER, Curran-Everett D, Erzurum SC, Ameredes BT, Bacharier L, et al. Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. J Allergy Clin Immunol 2007;119:405-13. https://doi.org/10.1016/j.jaci.2006.11.639
  7. The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. European Network for Understanding Mechanisms of Severe Asthma. Eur Respir J 2003;22:470-7. https://doi.org/10.1183/09031936.03.00261903
  8. Wenzel SE, Busse WW; National Heart, Lung, and Blood Institute's Severe Asthma Research Program. Severe asthma: lessons from the Severe Asthma Research Program. J Allergy Clin Immunol 2007;119:14-21. https://doi.org/10.1016/j.jaci.2006.10.025
  9. Reddel HK, Taylor DR, Bateman ED, Boulet LP, Boushey HA, Busse WW, et al. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med 2009;180:59-99. https://doi.org/10.1164/rccm.200801-060ST
  10. Bousquet J, Mantzouranis E, Cruz AA, Ait-Khaled N, Baena-Cagnani CE, Bleecker ER, et al. Uniform definition of asthma severity, control, and exacerbations: document presented for the World Health Organization Consultation on Severe Asthma. J Allergy Clin Immunol 2010;126:926-38. https://doi.org/10.1016/j.jaci.2010.07.019
  11. Chanez P, Wenzel SE, Anderson GP, Anto JM, Bel EH, Boulet LP, et al. Severe asthma in adults: what are the important questions? J Allergy Clin Immunol 2007;119:1337-48. https://doi.org/10.1016/j.jaci.2006.11.702
  12. Bel EH, Sousa A, Fleming L, Bush A, Chung KF, Versnel J, et al. Diagnosis and definition of severe refractory asthma: an international consensus statement from the Innovative Medicine Initiative (IMI). Thorax 2011 May 27 [Epub]. Available from: http://dx.doi.org/10.1136/thx.2010.153643.
  13. Bateman ED, Boushey HA, Bousquet J, Busse WW, Clark TJ, Pauwels RA, et al. Can guideline-defined asthma control be achieved? The gaining optimal asthma control study. Am J Respir Crit Care Med 2004;170:836-44. https://doi.org/10.1164/rccm.200401-033OC
  14. Pauwels RA, Lofdahl CG, Postma DS, Tattersfield AE, O'Byrne P, Barnes PJ, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 1997;337:1405-11. https://doi.org/10.1056/NEJM199711133372001
  15. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM; SMART Study Group. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006;129:15-26. https://doi.org/10.1378/chest.129.1.15
  16. Bailey W, Castro M, Matz J, White M, Dransfield M, Yancey S, et al. Asthma exacerbations in African Americans treated for 1 year with combination fluticasone propionate and salmeterol or fluticasone propionate alone. Curr Med Res Opin 2008;24:1669-82. https://doi.org/10.1185/03007990802119111
  17. Chowdhury BA, Dal Pan G. The FDA and safe use of long-acting beta-agonists in the treatment of asthma. N Engl J Med 2010;362:1169-71. https://doi.org/10.1056/NEJMp1002074
  18. Kramer JM. Balancing the benefits and risks of inhaled long-acting beta-agonists--the influence of values. N Engl J Med 2009;360:1592-5. https://doi.org/10.1056/NEJMp0810561
  19. Riley K, Jefferson E. FDA announces new safety controls for long-acting beta agonists, medications used to treat asthma [Internet]. Silver Spring, MD: Food and Drug Administration; 2010 [cited 2011 Aug 10]. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm200931.htm.
  20. National Heart, Lung, and Blood Institute (NHLBI). National asthma education and prevention program. Expert panel report 3: guidelines for the diagnois and management of asthma. Bethesda, MD: NHLBI; 2007.
  21. Nelson H, Bonuccelli C, Radner F, Ottosson A, Carroll KJ, Andersson TL, et al. Safety of formoterol in patients with asthma: combined analysis of data from double-blind, randomized controlled trials. J Allergy Clin Immunol 2010;125:390-6. https://doi.org/10.1016/j.jaci.2009.11.036
  22. de Vries F, Setakis E, Zhang B, van Staa TP. Long-acting $\beta$2-agonists in adult asthma and the pattern of risk of death and severe asthma outcomes: a study using the GPRD. Eur Respir J 2010;36:494-502. https://doi.org/10.1183/09031936.00124209
  23. Drazen JM, O'Byrne PM. Risks of long-acting beta-agonists in achieving asthma control. N Engl J Med 2009;360:1671-2. https://doi.org/10.1056/NEJMe0902057
  24. National Institute for Health and Clinical Excellence (NICE). Inhaled corticosteroids for the treatment of chronic asthma in adults and in children aged 12 years and over. NICE technology appraisal guidance 138. London, UK: NICE; 2008.
  25. Westby M, Benson M, Gibson P. Anticholinergic agents for chronic asthma in adults. Cochrane Database Syst Rev 2004;(3):CD003269.
  26. Rodrigo GJ, Castro-Rodriguez JA. Anticholinergics in the treatment of children and adults with acute asthma: a systematic review with meta-analysis. Thorax 2005;60:740-6. https://doi.org/10.1136/thx.2005.047803
  27. Gross NJ. Anticholinergic agents in asthma and COPD. Eur J Pharmacol 2006;533:36-9. https://doi.org/10.1016/j.ejphar.2005.12.072
  28. Ahmad Z, Singh SK. Relative and additional bronchodilator response of salbutamol and ipratropium in smoker and nonsmoker sthmatics. J Asthma 2010;47:340-3. https://doi.org/10.3109/02770900903584456
  29. Casaburi R, Mahler DA, Jones PW, Wanner A, San PG, ZuWallack RL, et al. A long-term evaluation of oncedaily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002;19:217-24. https://doi.org/10.1183/09031936.02.00269802
  30. Celli B, ZuWallack R, Wang S, Kesten S. Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest 2003;124:1743-8. https://doi.org/10.1378/chest.124.5.1743
  31. Terzano C, Petroianni A, Ricci A, D'Antoni L, Allegra L. Early protective effects of tiotropium bromide in patients with airways hyperresponsiveness. Eur Rev Med Pharmacol Sci 2004;8:259-64.
  32. Magnussen H, Bugnas B, van Noord J, Schmidt P, Gerken F, Kesten S. Improvements with tiotropium in COPD patients with concomitant asthma. Respir Med 2008;102:50-6. https://doi.org/10.1016/j.rmed.2007.08.003
  33. Gosens R, Bos IS, Zaagsma J, Meurs H. Protective effects of tiotropium bromide in the progression of airway smooth muscle remodeling. Am J Respir Crit Care Med 2005;171:1096-102. https://doi.org/10.1164/rccm.200409-1249OC
  34. Ohta S, Oda N, Yokoe T, Tanaka A, Yamamoto Y, Watanabe Y, et al. Effect of tiotropium bromide on airway inflammation and remodelling in a mouse model of asthma. Clin Exp Allergy 2010;40:1266-75. https://doi.org/10.1111/j.1365-2222.2010.03478.x
  35. Iwamoto H, Yokoyama A, Shiota N, Shoda H, Haruta Y, Hattori N, et al. Tiotropium bromide is effective for severe asthma with noneosinophilic phenotype. Eur Respir J 2008;31:1379-80. https://doi.org/10.1183/09031936.00014108
  36. Kapoor AS, Olsen SR, O'Hara C, Puttagunta L, Vethanayagam D. The efficacy of tiotropium as a steroid-sparing agent in severe asthma. Can Respir J 2009;16:99-101. https://doi.org/10.1155/2009/206506
  37. Park HW, Yang MS, Park CS, Kim TB, Moon HB, Min KU, et al. Additive role of tiotropium in severe asthmatics and Arg16Gly in ADRB2 as a potential marker to predict response. Allergy 2009;64:778-83. https://doi.org/10.1111/j.1398-9995.2008.01876.x
  38. Peters SP, Kunselman SJ, Icitovic N, Moore WC, Pascual R, Ameredes BT, et al. Tiotropium bromide step-up therapy for adults with uncontrolled asthma. N Engl J Med 2010;363:1715-26. https://doi.org/10.1056/NEJMoa1008770